# Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

> **NCT00742339** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of Padova** · enrollment: 49 (actual)

## Conditions studied

- Cirrhosis
- Hepatorenal Syndrome

## Interventions

- **DRUG:** Terlipressin plus albumin
- **DRUG:** Midodrine plus octreotide plus human albumin

## Key facts

- **NCT ID:** NCT00742339
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742339, "Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome". Retrieved via MORVS 2026-11-01 from https://api.morvs.ai/clinical/NCT00742339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*